DPP4 and diabetes mellitus: The patients who needed an intensification of antidiabetic therapy at 3-month follow-up with a molecule containing a combination of dapagliflozin and DPP4 inhibitors, which constituted 20% of the total subjects (9/45, 4 women, and 5 men), had a mean age of 61.6 ± 9.1 years and a diabetes duration of 9 ± 4.5 years.